Title of article
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
Author/Authors
Bell, Allison M. Department of Pharmacy Practice - University of Mississippi School of Pharmacy - Jackson - MS 39216, USA , Wagner, Jamie L. Department of Pharmacy Practice - University of Mississippi School of Pharmacy - Jackson - MS 39216, USA , Barber, Katie E. Department of Pharmacy Practice - University of Mississippi School of Pharmacy - Jackson - MS 39216, USA , Stover, Kayla R. Department of Pharmacy Practice - University of Mississippi School of Pharmacy - Jackson - MS 39216, USA - Department of Medicine-Infectious Diseases - University of Mississippi Medical Center - Jackson - MS 39216, USA
Pages
8
From page
1
To page
8
Abstract
Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment
modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately,
the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors
in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy
for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current
literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C.
Keywords
Hepatitis C virus , HCV , Elbasvir/Grazoprevir , Fight against Hepatitis C
Journal title
International Journal of Hepatology
Serial Year
2016
Record number
2595916
Link To Document